Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, reflects on the evolving treatment landscape of mesothelioma, highlighting combination immunotherapy as the new standard of care for this patient population. Dr Blyth also touches on current unmet needs such as therapeutic approaches for patients who do not respond to checkpoint inhibition, as well as optimal management of early-stage mesothelioma which is becoming of increased importance due to improvements in the diagnostic pathway. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, provides insights into the SYSTEMS-2 trial which suggests that mesothelioma may be more radiosensitive than generally thought. The study aimed to determine whether administering higher doses of radiotherapy better controls pain in patients with malignant pleural mesothelioma (MPM). While the results were not statistically significant, when considering the secondary endpoint of OS, an interesting survival difference was noted. This immature data suggests that higher-dose radiotherapy treatment could affect survival outcomes. This new research avenue feeds nicely into upcoming trials such as the HIT-Meso study (NCT05655078). This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

In this lecture mesothelioma, pathogenesis, presentation and different treatment modalities are discussed.

This channel aim at providing chest medicine and surgery review of literature and personal experience more than 25 years of practice. its an enrichment ebook. The objective is to provide a condense and consice reviews for each subject in 10 minutes to provide the audience (medical students and post graduates as well as professional surgeons) with updated science.
If you have any question to discuss do not hesitate to share.
All comments to improve the channel is welcomed.

In this video, we will discuss the detailed history pathology of Malignant mesothelioma

John Stahl was diagnosed with stage 4 pleural mesothelioma in 2019. Though most patients diagnosed in this stage are given just months to live, John is still alive today. Learn about John's journey.

Mesothelioma Hope can help you find top treatments, support, and legal aid right now. Call (866) 608-8933.

Presentation by Travis Grotz, MD, Mayo Clinic and Kiran Turaga, MD, University of Chicago about treatment for peritoneal mesothelioma including intraperitoneal chemotherapy, HIPEC, clinical trials, systemic therapies.